Breaking News
Translate

COVID-19: Nigeria won’t suspend hydroxychloroquine trial — NAFDAC

Kindly Share This Story:
COVID-19: Nigeria won’t suspend hydroxychloroquine trial — NAFDAC
COVID-19: Nigeria won’t suspend hydroxychloroquine trial — NAFDAC

Barely 24  hours after the World Health Organisation, WHO, suspended all clinical trials for hydroxychloroquine as a potential treatment for COVID-19, the National Agency for Food and Drug Administration and Control, NAFDAC, has said the trial will continue in Nigeria. The Director-General of the agency, Mojisola Adeyeye, stated this yesterday in an interview on a private television station.

The UN agency had on Monday said it had ‘temporarily’ suspended the clinical trials of hydroxychloroquine as a potential treatment for COVID-19 over safety concerns, adding that the decision followed a study in The Lancet that the use of the drug on COVID-19 patients could increase their likelihood of dying.

“The Executive Group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity Trial while the data is reviewed by the Data Safety Monitoring Board,“ WHO Director-General, Tedros Ghebreyesus had said.

READ ALSO: US issues emergency approval for remdesivir for COVID-19 patients

Chloroquine is a synthetic drug introduced in the 1940s.  It is a member of an important series of chemically related agents known as quinoline derivatives. Hydroxychloroquine is a related compound that was introduced in 1955.

But Mrs Adeyeye said there were proven records that hydroxychloroquine had been effective in the treatment of COVID-19 patients.

According to her, this is most effective in those at the mild stage of the virus.  “There is data to prove that hydroxychloroquine worked for many COVID-19 patients. Therefore, we would continue our own clinical trials in Nigeria. Hydroxychloroquine has been proved to work at a mild stage. So the potency depends on the severity of the disease in the patient’s body,” she said.

Vanguard

Kindly Share This Story:
All rights reserved. This material and any other digital content on this platform may not be reproduced, published, broadcast, written or distributed in full or in part, without written permission from VANGUARD NEWS.

Disclaimer

Comments expressed here do not reflect the opinions of vanguard newspapers or any employee thereof.
Do NOT follow this link or you will be banned from the site!